Compare Cassava Sciences Inc (FLNA) vs Franco-Nevada Corporation (FNV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Franco-Nevada Corporation — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.34M), while Franco-Nevada Corporation trades at $236.47 (market cap $45.36B). The key difference: Franco-Nevada Corporation is far larger — about 1283.5× Cassava Sciences Inc's market cap, and Franco-Nevada Corporation pays a 0.75% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Franco-Nevada Corporation for 0 Days on average.
| FLNA | FNV | |
|---|---|---|
Market Cap | $35.34M | $45.36B |
Volume | 251,946 | 787,841 |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $280.82 |
52-Week Low | $0.68 | $183.97 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$47.34M | $44.34B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite oscillator bullishness. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent FDA approval to lift the clinical hold on simufilam for TSC-related epilepsy is a positive development, with Phase 2a trials expected in early 2027.
Outlook remains speculative given negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include ongoing operational losses and dependence on clinical trial success. The stock presents high-risk biotech opportunity with potential upside from successful drug development.
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →
